ReviewJournal of Cancer2021
Chimeric antigen receptor T-cell immunotherapy in breast cancer: development and challenges.
Review in Journal of Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Listening to Immunotherapy - Ultrasound and Photoacoustic Imaging Strategies to Guide and Enhance Cancer Treatments.Molecular imaging and biology · 2026Review
- Advancing breast cancer treatment through dual targeting CAR T cell therapy.Discover oncology · 2025Review
- Global research trends in CAR-T cell therapy for glioblastoma: a bibliometric and visualized analysis.Discover oncology · 2025Article
- CAR-T cell therapy and reconstructive oncologic surgery in peripheral solid tumors-A narrative review.Cell reports. Medicine · 2025Review
- Article
- Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.Oncogene · 2025Review
- Breast cancer immunotherapy: Realities and advances.Cancer innovation · 2024Review
- 9S1R nullomer peptide induces mitochondrial pathology, metabolic suppression, and enhanced immune cell infiltration, in triple-negative breast cancer mouse model.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024Article
- Journey of CAR T‑cells: Emphasising the concepts and advancements in breast cancer (Review).International journal of oncology · 2023Review
- Core fucosylation and its roles in gastrointestinal glycoimmunology.World journal of gastrointestinal oncology · 2023Review
- Nullomer peptide increases immune cell infiltration and reduces tumor metabolism in triple negative breast cancer mouse model.Research square · 2023Article
- Novel chimeric antigen receptor T cell-based immunotherapy: a perspective for triple-negative breast cancer.Frontiers in cell and developmental biology · 2023Review
- Chemotherapeutics and CAR-T Cell-Based Immunotherapeutics Screening on a 3D Bioprinted Vascularized Breast Tumor Model.Advanced functional materials · 2022Article
- Review
- N6-Methyladenosine Methylation Regulator RBM15 is a Potential Prognostic Biomarker and Promotes Cell Proliferation in Pancreatic Adenocarcinoma.Frontiers in molecular biosciences · 2022Article
- Insulin-like growth factor 2 receptor is a key immune-related gene that is correlated with a poor prognosis in patients with triple-negative breast cancer: A bioinformatics analysis.Frontiers in oncology · 2022Article
- Assessment of CAR-T Cell-Mediated Cytotoxicity in 3D Microfluidic Cancer Co-Culture Models for Combination Therapy.IEEE open journal of engineering in medicine and biology · 2022Article
- Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Chimeric antigen receptor (CAR) T-cell therapy is an innovative form of immunotherapy wherein autologous T-cells are genetically modified to express chimeric receptors encoding an antigen-specific single-chain variable fragment and costimulatory molecules. Moreover, CAR T-cell therapy can only work successfully in patients who have an intact immune system. Therefore, patients receiving cytotoxic chemotherapy will be immunosuppressed making CAR-T therapy less effective. In adoptive CD8+ T-cell therapy (ACT), numerous tumor-specific, engineered T-cells are sourced from patients, expanded
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.